Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Patients' rationale for declining participation in a cancer‐associated weight loss study
Wanger, Tammy, Foster, Nathan R. , Jatoi, Aminah , Nguyen, Phuong

Mayo Clinic

Journal of Cachexia, Sarcopenia and Muscle | March 12, 2014 | Volume: 5 | Issue: 2 | Pages: 121-125

10.1007/s13539-014-0128-z | PMID 24622952 Get It

BackgroundFewer than 5 % of cancer patients participate in clinical research. Although this paltry rate has led to extensive research on this topic, previous studies have not sought verbatim comments in a real‐time, comprehensive manner to understand why patients decline.MethodsThis study used a low‐risk, non‐interventional parent study that focused on cancer‐associated weight loss to understand patients' reasons for declining research participation. A research assistant wrote down the name and verbatim reason of all patients who declined to participate. These comments with accompanying patient demographic data are the subject of this report.ResultsOf the 334 patients, 51 (15 %) declined parent study enrollment; three comment‐related themes emerged: (1) a repelling sense of too much institutional research, (2) overwhelming personal health issues, and (3) a low likelihood of returning to the institution. In univariate and multivariate analyses, only age (older) and gender (female) were associated with non‐enrollment. Interestingly, 41 patients with fatigue scores of 7 or worse and 26 with pain scores of 7 or worse were enrolled.ConclusionsAlthough many factors were associated with declining to participate in research, symptom severity was not. Upfront education might help cancer patients better prioritize their participation in research, particularly as some patients felt overwhelmed by too much research in the institution; and for now, investigators should continue to keep asking patients for their participation.
Approximately one‐half of patients with early‐stage hepatocellular carcinoma meeting Milan criteria did not receive local tumor destructive or curative surgery in the post‐MELD exception era
Devaki, Pardha, Wong, Robert J. , Marupakula, Vidyasagargoud, Nangia, Sharad, Ditah, Ivo, Ehrinpreis, Murray N., Nguyen, Mindie H. , Nguyen, Long H. , Wong, Robert J

Mayo Clinic

Cancer | March 3, 2014 | Volume: 120 | Issue: 11 | Pages: 1725-1732

10.1002/cncr.28639 | PMID 24590359 Get It

BACKGROUNDSince 2002, priority Model for End‐stage Liver Disease (MELD) exception status has been given to patients with hepatocellular carcinoma (HCC) who meet the Milan criteria. Since then, the number of liver transplantations performed in patients with HCC has increased, but to the authors' knowledge, few studies to date have examined the effect of MELD exception recommendations on therapy use and survival rates in a nationwide sample. The current study examines therapy use and long‐term survival rates among patients with HCC tumors meeting the Milan criteria in the post‐MELD exception era.METHODSThe current study is a retrospective cohort study of 2179 patients with localized HCC meeting the Milan criteria who were registered between 2004 and 2007 in the Surveillance, Epidemiology, and End Results database.RESULTSA total of 43% of patients did not receive any specific therapy. Overall, the 5‐year relative survival rate for patients receiving only supportive care was dismal at 24% (95% confidence interval [95% CI], 21%‐27%), whereas that for patients undergoing liver transplantation was 77% (95% CI, 71%‐82%). Long‐term survival was found to be dependent on age, race/ethnicity, and type of therapy received. A multivariate Cox proportional hazards model adjusted for age, race/ethnicity, and type of therapy received demonstrated that, compared with white patients, black patients had significantly poorer survival outcomes (hazards ratio, 1.23; 95% CI, 1.03‐1.47 [P = .02]), whereas Asian/Pacific Islander patients had significantly better survival rates when compared with white patients (HR, 0.66; 95% CI, 0.57‐0.77 [P < .001]).CONCLUSIONSDespite having localized disease that met transplantation criteria, nearly 50% of the large nationwide cohort of patients with HCC in the current study received only supportive care and had dismal 5‐year relative survival rates, especially among black patients. Cancer 2014;120:1725–1732. © 2014 American Cancer Society.
Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease
Belcher, John D. , Chen, Chunsheng , Nguyen, Julia , Milbauer, Liming , Abdulla, Fuad , Alayash, Abdu I. , Smith, Ann , Nath, Karl A. , Hebbel, Robert P. , Vercellotti, Gregory M.

Mayo Clinic

Blood | November 26, 2013 | Volume: 123 | Issue: 3 | Pages: 377-390

10.1182/blood-2013-04-495887 | PMID 24277079 Get It

Key Points Heme, released from hemoglobin, elicits vaso-occlusion in transgenic sickle mice via endothelial TLR4 signaling. Heme/TLR4 signaling activates NF-κB and triggers vaso-occlusion through Weibel-Palade body degranulation and adhesion molecule expression.
Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
Galon, Jérôme , Mlecnik, Bernhard , Bindea, Gabriela , Berger, Anne, Lagorce, Christine, Lugli, Alessandro , Zlobec, Inti , Hartmann, Arndt , Bifulco, Carlo , Nagtegaal, Irıs D. , Masucci, Giuseppe , Botti, Gerardo , Tatangelo, Fabiana , Delrio, Paolo , Maio, Michele , Laghi, Luigi , Grizzi, Fabio , Asslaber, Martin, D’Arrigo, Corrado, Vidal‐Vanaclocha, Fernando, Závadová, Eva, Ohashi, Pamela S. , Hafezi‐Bakhtiari, Sara, Wouters, Bradly G. , Roehrl, Michael H. A. , Nguyen, Linh N, Kawakami, Yutaka , Hazama, Shoichi , Okuno, Kiyotaka, Ogino, Shuji , Gibbs, Peter , Waring, Paul , Sato, Noriyuki , Itoh, Kyogo, Patel, Prabhudas S. , Shukla, Shilin N., Wang, Yili , Kopetz, Scott , Scripcariu, Viorel , Ascierto, Paolo A. , Marincola, Francesco M. , Fox, Bernard A. , Pagès, Franck , Angell, Helen K. , Palmqvist, Richard , Chouchane, Lotfi , Ogino, Shuji , Torigoe, Toshihiko , Sinicrope, Frank A. , Galon, Jerome , Kopetz, Scott , Nagtegaal, Iris D

Mayo Clinic

The Journal of Pathology | October 11, 2013 | Volume: 232 | Issue: 2 | Pages: 199-209

10.1002/path.4287 | PMID 24122236 Get It

Abstract The American Joint Committee on Cancer/Union Internationale Contre le Cancer ( AJCC / UICC ) TNM staging system provides the most reliable guidelines for the routine prognostication and treatment of colorectal carcinoma. This traditional tumour staging summarizes data on tumour burden (T), the presence of cancer cells in draining and regional lymph nodes (N) and evidence for distant metastases (M). However, it is now recognized that the clinical outcome can vary significantly among patients within the same stage. The current classification provides limited prognostic information and does not predict response to therapy. Multiple ways to classify cancer and to distinguish different subtypes of colorectal cancer have been proposed, including morphology, cell origin, molecular pathways, mutation status and gene expression‐based stratification. These parameters rely on tumour‐cell characteristics. Extensive literature has investigated the host immune response against cancer and demonstrated the prognostic impact of the in situ immune cell infiltrate in tumours. A methodology named ‘Immunoscore’ has been defined to quantify the in situ immune infiltrate. In colorectal cancer, the Immunoscore may add to the significance of the current AJCC / UICC TNM classification, since it has been demonstrated to be a prognostic factor superior to the AJCC / UICC TNM classification. An international consortium has been initiated to validate and promote the Immunoscore in routine clinical settings. The results of this international consortium may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM ‐I ( TNM ‐Immune). © 2013 The Authors. Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
P3–009: Association study of late‐onset Alzheimer's disease risk variants and risk for posterior cortical atrophy
Carrasquillo, Minerva M. , Khan, Qurat ul Ain , Murray, Melissa E. , Nguyen, Thuy , Bisceglio, Gina, Younkin, Steven G. , Graff‐Radford, Neill R. , Ertekin‐Taner, Nilüfer , Carrasquillo, Minerva M. , Krishnan, Siddharth , Ma, Li , Dickson, Dennis W. , Boeve, Bradley F. , Murray, Melissa E

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_14 | Pages: No page available

10.1016/j.jalz.2013.05.1078 Get It

P4–004: Association study of late‐onset Alzheimer's disease risk variants and memory decline
Carrasquillo, Minerva M. , Pedraza, Otto , Allen, Mariet , Nguyen, Thuy , Malphrus, Kimberly G., Bisceglio, Gina, Roberts, Rosebud O., Lucas, John A. , Ivnik, Robert J., Graff‐Radford, Neill, Petersen, Ronald C. , Younkin, Steven G. , Ertekin‐Taner, Nilüfer , Carrasquillo, Minerva M. , Crook, Julia E. , Pankratz, V. Shane , Ma, Li , Machulda, Mary M. , Graff‐Radford, Neill

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_17 | Pages: No page available

10.1016/j.jalz.2013.05.1392 Get It

Pretreatment of Small-for-Size GraftsIn Vivobyγ-Aminobutyric Acid Receptor Regulation against Oxidative Stress-Induced Injury in Rat Split Orthotopic Liver Transplantation
Hori, Tomohide , Üemoto, Shinji , Walden, Lindsay B., Baine, Ann‐Marie T., Nguyen, Justin H. , Chen, Feng , Hata, Toshiyuki

Mayo Clinic

International Journal of Hepatology | October 8, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-13

10.1155/2013/149123 | PMID 24223309 Get It

Background. Graft pretreatment to limit postoperative damage has the advantage of overcoming a current issue in liver transplantation (LT). The strategic potential of graft pretreatmentin vivoby a specific agonist forγ-aminobutyric acid receptor (GABAR) was investigated in the rat LT model with a small-for-size graft (SFSG).Methods. Recipient rats were divided into three groups according to donor treatments and recipient surgeries: (i) saline and laparotomy, (ii) saline and split orthotopic liver transplantation (SOLT) with 40%-SFSG, and (iii) GABAR agonist and SOLT with 40%-SFSG. Survival was evaluated. Blood and liver samples were collected 6 h after surgery. Immunohistological assessment for apoptotic induction and western blotting for 4-hydroxynonenal, ataxia-telangiectasia mutated kinase (ATM), histone H2AX, phosphatidylinositol-3 kinase (PI3K), Akt, and free radical scavenging enzymes were performed.Results. Pretreatment by GABAR showed improvement in survival, histopathological assessment, and biochemical tests. Apoptotic induction and oxidative stress were observed after SOLT with an SFSG, and this damage was limited by GABAR regulation. GABAR regulation appeared to reduce DNA damage via the ATM/H2AX pathway and to promote cell survival via the PI3K/Akt pathway.Conclusions. Pretreatmentin vivoby GABAR regulation improves graft damage after SOLT with an SFSG. This strategy may be advantageous in LT.
A national survey of radiation oncologists and urologists on recommendations of prostate‐specific antigen screening for prostate cancer
Kim, Simon P. , Karnes, R. Jeffrey , Nguyen, Paul L. , Thompson, R. Houston, Han, Leona C., Shah, Nilay D., Smaldone, Marc C. , Gross, Cary P. , Frank, Igor, Weight, Christopher , Beebe, Timothy J. , Tilburt, Jon C. , Ziegenfuss, Jeanette Y. , Beebe, Timothy J.

Mayo Clinic

BJU International | August 23, 2013 | Volume: 113 | Issue: 5b | Pages: No page available

10.1111/bju.12422 | PMID 24053213 Get It

Objective To assess recommendations for prostate‐specific antigen ( PSA ) screening in a national survey of radiation oncologists and urologists following the recent USA P reventive S ervices T ask F orce ( USPSTF ) grade D recommendation. Methods A random sample of 1366 radiation oncologists and urologists were identified from the A merican M edical A ssociation P hysician M asterfile. From N ovember 2011 to A pril 2012, a mail survey was sent to query PSA screening recommendations for men at average risk of prostate cancer for the following age groups: 40–49, 50–59, 60–69, 70–74, 75–79 and ≥80 years. Multivariable logistic regression was used to test for differences in PSA ‐based screening recommendations by physician characteristics. Results Response rates were similar at 52% for radiation oncologists and urologists ( P = 0.92). Overall, 51.5% of respondents recommended PSA ‐based screening for men aged 40–49 years, while nearly all endorsed it for those aged 50–74 years (96.1% for 50–59, 97.3% for 60–69, and 87.7% for 70–74 years). However, screening recommendations decreased to 43.9% and 12.8% for men aged 75–79 and ≥80 years, respectively. On multivariable analysis, urologists were more likely to recommend screening for men aged 40–49 (odds ratio [ OR ] 3.09; P < 0.001) and 50–59 years ( OR 3.81; P = 0.01), but less likely for men aged 75–79 ( OR 0.66; P = 0.01) and ≥80 years ( OR 0.45; P = 0.002) compared with radiation oncologists. Conclusion While radiation oncologists and urologists recommended PSA screening for men aged 50–69 years, there was less agreement about screening for younger (40–49 years old) and older (≥70 years) men at average risk for prostate cancer.
Effectiveness of PET/CT in the preoperative evaluation of neck disease
Nguyen, Anthony , Luginbuhl, Adam , Cognetti, David M. , Abel, Katie Van, Bar‐Ad, Voichita , Intenzo, Charles , Keane, William M., Curry, Joseph

Mayo Clinic

The Laryngoscope | July 30, 2013 | Volume: 124 | Issue: 1 | Pages: 159-164

10.1002/lary.24329 | PMID 23901035 Get It

Objectives/HypothesisTo evaluate the utility of positron emission tomography (PET)/computed tomography (CT) for staging the neck in the preoperative setting by comparing it to both CT/magnetic resonance imaging (MRI) and pathologic staging.Study DesignRetrospective review.MethodsSeventy‐one patients with initial diagnosis of head and neck squamous cell carcinoma having preoperative MR or CT imaging and PET/CT with subsequent bilateral neck dissection as part of primary treatment (142 neck dissections). Comparison of cervical nodal metastases based on three separate staging systems: preoperative CT and/or MRI scan, preoperative PET/CT, and pathology.ResultsBoth CT/MRI scans and PET/CT scans statistically predicted pathologic outcomes (P = 0.0001, P = 0.0001, respectively) using Chi square analysis. There was a statistically significant improvement in the prediction of true pathologic disease using PET/CT compared to CT and/or MRI alone (P = 0.005). In a subgroup analysis including only the contralateral neck, this significance persisted (P = 0.013). McNemar's test revealed that subsequent detection of bilateral neck disease by PET/CT scan was significantly superior to MRI or CT alone (P = 0.023).ConclusionIn pathologically positive necks, PET/CT was statistically more reliable at identifying positive disease than CT or MRI alone. Furthermore, such a result is achieved without a statistically significant difference in false positivity between PET/CT and CT or MRI. This suggests that PET/CT positivity, despite negative clinical exam and CT/MRI findings, may be more likely to signify pathologic disease and require appropriate treatment.Level of Evidence4. Laryngoscope, 124:159–164, 2014